Original Research ArticleInternational Journal of Research in Dermatology

Publication:
Efficacy and tolerability of a multi-ingredient nutraceutical on facial skin ageing parameters and self-reported wellbeing: a prospective, open-label and single-arm pilot study

Int J Res Dermatol. 2026.DOI10.18203/issn.2455-4529.IntJResDermatol20263696

Thumbnail Image
Read online (HTML) View on the journal's website(opens in a new tab)

Abstract

Background Skin ageing involves interconnected changes in extracellular matrix integrity, hydration, oxidative stress and cellular resilience. This study evaluated the efficacy and tolerability of RESET by IQ HEALTH™, a multi-ingredient oral nutraceutical, in adults with visible facial skin ageing.

Methods This prospective, open-label, single-arm clinical study enrolled healthy adults aged 35-55 years with facial skin ageing. Participants consumed one sachet daily for 60 days. Facial firmness (Cutometer R0), elasticity (Cutometer R7), and hydration [MoistureMeter SC (MMSC)] were assessed at baseline, day 30, and day 60. Participant-reported skin and wellness outcomes and tolerability were assessed descriptively.

Results Thirty-four participants-initiated supplementation and 33 completed the study. At day 60, firmness improved by 38.9%, elasticity by 8.9%, and hydration by 19.2% from baseline (all p<0.001). Significant changes were observed at day 30. At day 60, 84.9% reported firmer/tighter facial skin, 81.8% reported a younger appearance, and 90.9% reported improved moisturization and hydration. Exploratory improvements were also reported in energy, joint comfort, sleep quality, fatigue, relaxation, and muscle soreness. The product was generally well tolerated; gastrointestinal symptoms were mild and infrequent, with no serious adverse events or treatment-related discontinuations.

Conclusions Daily supplementation with RESET by IQ HEALTH™ for 60 days was associated with improvements in facial skin firmness, elasticity, and hydration, together with favourable participant-reported skin and wellness outcomes. These findings are preliminary given the single-arm, open-label design and small sample size and require confirmation in randomized, placebo-controlled studies.

Keywords

Affiliations

  1. Svista India Private Limited, Bengaluru, Karnataka, India
  2. Fresenius Kabi Oncology Limited, Gurugram, India
  3. C.L.A.I.M.S. Private Limited, Mumbai, Maharashtra, India

Full item record